DualityBio’s DB-1303 Granted Fast-Track Status by FDA for Advanced Endometrial Cancer Treatment
Duality Biologics has announced that the FDA has granted Fast Track Designation to DB-1303, a novel antibody-drug conjugate, for the treatment of advanced, recurrent or metastatic endometrial carcinom ...